C-CAR168: A Novel Bispecific CAR-T Therapy for Autoimmune Diseases Showcased at ACR Convergence 2024
AbelZeta
Developer of Immune Cell and Stem Cell Therapy Products
November 19, 2024
eMedClub News
Rockville, Maryland, USA, November 16, 2024 -- Cellular Biomedicine Group (referred to as "Cellular Biomedicine" or "the Company"), a global biopharmaceutical company at the clinical stage focused on the discovery and development of innovative cell therapies, announced itsPreclinical Data of C-CAR168 StudyHeld from November 14 to 19, 2024, in Washington, D.C.American College of Rheumatology (ACR) Annual MeetingPublished in the form of a special report. C-CAR168 is a novel bispecific autologous CAR-T therapy targeting CD20 and B-cell maturation antigen (BCMA), aimed at treating patients with lupus nephritis and systemic lupus erythematosus who are unresponsive to conventional treatments. The U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) application for C-CAR168 in May 2024.
Abstract Information
Title:C-CAR168, a Novel Bispecific CAR-T Therapy for Treating Autoimmune Diseases
Abstract Number:0876
Conference Theme:T Cell Biology and Targets in Autoimmune Inflammatory Diseases
Meeting Time:November 16, 2024, Eastern Time 15:00-16:30
Reporting Location:Room 143ABC, Washington Convention Center
Report Time:November 16, 2024, Eastern Time 16:00-16:15
Key Research Highlights
Cellular Biomedicine GroupComprehensive preclinical studies have been conducted on the biological characteristics of C-CAR168. Preclinical experiments show that C-CAR168 can be specifically activated by CD20 and/or BCMA targets on the cell surface, effectively killing CD20 and/or BCMA positive target cells, and can eliminate the significantly expanded ABC cell subpopulation in autoimmune diseases.
In immunodeficient mouse models, C-CAR168 demonstrated excellent in vivo activity, successfully inhibiting the growth of CD20 and BCMA single-positive or double-positive target cells.
Comprehensive analysis, including whole-genome membrane protein array, confirmed that C-CAR168 specifically targets CD20 and BCMA proteins, with no significant binding to non-target cells.
In vitro studies show that the therapy has low genotoxicity andGood Safety。
"C-CAR168's progress is encouraging. We believe this drug has the potential to offer an excellent treatment option for patients with various refractory autoimmune diseases who are severely affected clinically and have a poor prognosis."CEO of Cellular Biomedicine Group (Shanghai) Ltd, Liu Bizuo"This progress marks another important step forward in our efforts to provide potential best-in-class and/or disease-best innovative cell therapies for cancer, inflammation, and immune diseases."
Dr. Yao Yihong, Chief Scientific Officer of Cellular Biomedicine Group (Shanghai) Ltd"We are very excited about the potential of C-CAR168. Research has shown that CD20 is a highly effective target that can deplete B cells and treat relapsed/refractory non-Hodgkin lymphoma (r/r NHL). Other approved therapies also confirm the promising future of CD20 in treating autoimmune diseases. Our CAR-T therapies targeting CD20 and BCMA have been proven safe and effective in non-Hodgkin lymphoma and multiple myeloma, respectively. The design goal of C-CAR168 is to recognize and kill B cells, plasmablasts, and long-lived plasma cells to eliminate the source of autoantibodies, thereby providing a fundamental treatment for various severe autoimmune diseases (including lupus nephritis and systemic lupus erythematosus) that are currently unresponsive to existing therapies."
About Cellular Biomedicine Group
Cellular Biomedicine Group is a clinical-stage global biopharmaceutical company with innovation centers in Maryland, USA, and Shanghai, China. It focuses on developing innovative cell therapy products and is committed to combating malignant hematologic tumors, solid tumors, as well as inflammatory and immune diseases through personalized treatments that harness the body's own immune system. The company has GMP-compliant production facilities at each of its innovation centers to advance product development and early clinical research, with a pipeline covering CAR-T and TIL therapies.
For more information, please visit the official website of Cellular Biomedicine Group (Shanghai) Ltd at https://www.abelzeta.com/.
Forward-Looking Statements
The statements in this communication related to plans, strategies, specific activities, and other descriptions that are not historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties. Due to various factors, including any risks detailed from time to time in the company’s reports, actual results may differ materially from current expectations. These statements are based on the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties outside the company’s control. In light of these uncertainties, you should not place undue reliance on these forward-looking statements, which are only valid as of the date of this document. Unless required by law, the company assumes no obligation and expressly disclaims any obligation to update, alter, or otherwise revise any forward-looking statements made orally or in writing from time to time, whether due to new information, future events, or other reasons.
DianDian "Share”、“Like" and "In View", charge me up a bit~"